Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines
Author:
Özden-Yılmaz Gülden1ORCID, Savas Busra12, Bursalı Ahmet1, Eray Aleyna12, Arıbaş Alirıza1, Senturk Serif12ORCID, Karaca Ezgi12ORCID, Karakülah Gökhan12ORCID, Erkek-Ozhan Serap1
Affiliation:
1. Izmir Biomedicine and Genome Center, Inciralti, 35340 Izmir, Turkey 2. Izmir International Biomedicine and Genome Institute, Dokuz Eylül University, Inciralti, 35340 Izmir, Turkey
Abstract
Epigenetic deregulation is a critical theme which needs further investigation in bladder cancer research. One of the most highly mutated genes in bladder cancer is KDM6A, which functions as an H3K27 demethylase and is one of the MLL3/4 complexes. To decipher the role of KDM6A in normal versus tumor settings, we identified the genomic landscape of KDM6A in normal, immortalized, and cancerous bladder cells. Our results showed differential KDM6A occupancy in the genes involved in cell differentiation, chromatin organization, and Notch signaling depending on the cell type and the mutation status of KDM6A. Transcription factor motif analysis revealed HES1 to be enriched at KDM6A peaks identified in the T24 bladder cancer cell line; moreover, it has a truncating mutation in KDM6A and lacks a demethylase domain. Our co-immunoprecipitation experiments revealed TLE co-repressors and HES1 as potential truncated and wild-type KDM6A interactors. With the aid of structural modeling, we explored how truncated KDM6A could interact with TLE and HES1, as well as RUNX and HHEX transcription factors. These structures provide a solid means of studying the functions of KDM6A independently of its demethylase activity. Collectively, our work provides important contributions to the understanding of KDM6A malfunction in bladder cancer.
Funder
L’Oreal-UNESCO National for Women in Science Program L’Oreal-UNESCO International Rising Talent Program The Scientific and Technological Research Council of Turkey EMBO Installation Grant
Reference67 articles.
1. Targeting Epigenetics in Cancer;Bennett;Annu. Rev. Pharmacol. Toxicol.,2018 2. Robertson, A.G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A.D., Hinoue, T., Laird, P.W., Hoadley, K.A., and Akbani, R. (2017). Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 171. 3. Treatment of muscle-invasive and advanced bladder cancer in 2020;Patel;CA Cancer J. Clin.,2020 4. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade;Goel;Asian J. Urol.,2019 5. Koch, J., Lang, A., Whongsiri, P., Schulz, W.A., Hoffmann, M.J., and Greife, A. (2021). KDM6A mutations promote acute cytoplasmic DNA release, DNA damage response and mitosis defects. BMC Mol. Cell Biol., 22.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|